(FRE) Fresenius SE & Co. KGaA - Ratings and Ratios
Dialyzers, Infusion, Nutrition, Devices
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 22.6% |
| Value at Risk 5%th | 34.3% |
| Relative Tail Risk | -7.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.70 |
| Alpha | 43.70 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.510 |
| Beta | 0.016 |
| Beta Downside | 0.049 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.08% |
| Mean DD | 6.35% |
| Median DD | 4.53% |
Description: FRE Fresenius SE & Co. KGaA October 14, 2025
Fresenius SE & Co. KGaA (XETRA:FRE) is a German-based, diversified health-care group that serves chronically ill patients through four operating segments: Fresenius Medical Care (dialysis products and services), Fresenius Kabi (critical-care nutrition, infusion therapies, and medical devices), Fresenius Helios (hospital and nursing-care facilities), and Fresenius Vamed (health-care facility management and patient services). The company traces its roots to 1912 and adopted its current legal form in 2011.
Key financial metrics (FY 2023) show total revenue of €41.0 bn, with Fresenius Medical Care contributing roughly 55 % of that total. The segment’s EBITDA margin hovered around 30 % on a reported basis, reflecting high-margin recurring dialysis services, while Fresenius Kabi delivered a 12 % EBITDA margin, driven by growth in parenteral nutrition and infusion-pump sales.
Sector drivers that materially affect FRE’s outlook include: (1) demographic aging and rising prevalence of chronic kidney disease, which underpins long-term demand for dialysis; (2) tightening reimbursement regimes in Europe and the United States, pressuring pricing power; and (3) supply-chain resilience for sterile manufacturing, a critical factor for Fresenius Kabi’s nutrition and infusion products.
For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of FRE’s valuation multiples and scenario analyses.
FRE Stock Overview
| Market Cap in USD | 30,602m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | |
| Return 12m vs S&P 500 | 27.9% |
| Analyst Rating | - |
FRE Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 2.10% |
| Yield on Cost 5y | 2.91% |
| Yield CAGR 5y | -18.15% |
| Payout Consistency | 81.3% |
| Payout Ratio | 30.2% |
FRE Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 25.69% |
| CAGR/Max DD Calmar Ratio | 1.16 |
| CAGR/Mean DD Pain Ratio | 4.04 |
| Current Volume | 858.1k |
| Average Volume | 714.6k |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.12b TTM) > 0 and > 6% of Revenue (6% = 1.33b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -4.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.63% (prev 12.06%; Δ -0.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 2.21b > Net Income 1.12b (YES >=105%, WARN >=100%) |
| Net Debt (11.63b) to EBITDA (3.33b) ratio: 3.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (569.0m) change vs 12m ago 0.67% (target <= -2.0% for YES) |
| Gross Margin 25.40% (prev 23.25%; Δ 2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.40% (prev 51.39%; Δ 1.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.83 (EBITDA TTM 3.33b / Interest Expense TTM 379.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.52
| (A) 0.06 = (Total Current Assets 10.88b - Total Current Liabilities 8.30b) / Total Assets 41.32b |
| (B) 0.34 = Retained Earnings (Balance) 14.04b / Total Assets 41.32b |
| (C) 0.05 = EBIT TTM 2.21b / Avg Total Assets 42.42b |
| (D) 0.62 = Book Value of Equity 13.97b / Total Liabilities 22.38b |
| Total Rating: 2.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.30
| 1. Piotroski 4.50pt |
| 2. FCF Yield 3.25% |
| 3. FCF Margin 5.57% |
| 4. Debt/Equity 0.70 |
| 5. Debt/Ebitda 3.49 |
| 6. ROIC - WACC (= 0.78)% |
| 7. RoE 5.92% |
| 8. Rev. Trend -82.06% |
| 9. EPS Trend 70.19% |
What is the price of FRE shares?
Over the past week, the price has changed by +0.25%, over one month by -3.50%, over three months by +0.72% and over the past year by +46.26%.
Is FRE a buy, sell or hold?
What are the forecasts/targets for the FRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.8 | 12.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 54.2 | 13.7% |
FRE Fundamental Data Overview November 25, 2025
Market Cap EUR = 26.58b (26.58b EUR * 1.0 EUR.EUR)
P/E Trailing = 23.0244
P/E Forward = 12.9534
P/S = 1.1844
P/B = 1.4197
P/EG = 0.3809
Beta = 0.921
Revenue TTM = 22.23b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.33b EUR
Long Term Debt = 9.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.26b EUR (from shortTermDebt, last quarter)
Debt = 12.85b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.63b EUR (from netDebt column, last quarter)
Enterprise Value = 38.05b EUR (26.58b + Debt 12.85b - CCE 1.39b)
Interest Coverage Ratio = 5.83 (Ebit TTM 2.21b / Interest Expense TTM 379.0m)
FCF Yield = 3.25% (FCF TTM 1.24b / Enterprise Value 38.05b)
FCF Margin = 5.57% (FCF TTM 1.24b / Revenue TTM 22.23b)
Net Margin = 5.06% (Net Income TTM 1.12b / Revenue TTM 22.23b)
Gross Margin = 25.40% ((Revenue TTM 22.23b - Cost of Revenue TTM 16.58b) / Revenue TTM)
Gross Margin QoQ = 26.12% (prev 24.97%)
Tobins Q-Ratio = 0.92 (Enterprise Value 38.05b / Total Assets 41.32b)
Interest Expense / Debt = 0.67% (Interest Expense 86.0m / Debt 12.85b)
Taxrate = 29.74% (146.0m / 491.0m)
NOPAT = 1.55b (EBIT 2.21b * (1 - 29.74%))
Current Ratio = 1.31 (Total Current Assets 10.88b / Total Current Liabilities 8.30b)
Debt / Equity = 0.70 (Debt 12.85b / totalStockholderEquity, last quarter 18.28b)
Debt / EBITDA = 3.49 (Net Debt 11.63b / EBITDA 3.33b)
Debt / FCF = 9.40 (Net Debt 11.63b / FCF TTM 1.24b)
Total Stockholder Equity = 19.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.72% (Net Income 1.12b / Total Assets 41.32b)
RoE = 5.92% (Net Income TTM 1.12b / Total Stockholder Equity 19.01b)
RoCE = 7.80% (EBIT 2.21b / Capital Employed (Equity 19.01b + L.T.Debt 9.31b))
RoIC = 5.02% (NOPAT 1.55b / Invested Capital 30.88b)
WACC = 4.25% (E(26.58b)/V(39.44b) * Re(6.07%) + D(12.85b)/V(39.44b) * Rd(0.67%) * (1-Tc(0.30)))
Discount Rate = 6.07% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 81.65 | Cagr: 0.51%
[DCF Debug] Terminal Value 76.54% ; FCFE base≈2.05b ; Y1≈1.83b ; Y5≈1.56b
Fair Price DCF = 49.97 (DCF Value 28.14b / Shares Outstanding 563.2m; 5y FCF grow -13.08% → 3.0% )
EPS Correlation: 70.19 | EPS CAGR: 49.77% | SUE: 0.39 | # QB: 0
Revenue Correlation: -82.06 | Revenue CAGR: -20.42% | SUE: 0.08 | # QB: 0